Read the latest news about LamKap Bio Group
New publication : Development and characterization of NILK-2301
A novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
LamKap Bio presented data on NILK-2301, NILK-2401 & NILK-3301
LamKap Bio presented data on NILK-2301, NILK-2401 & NILK-3301
LamKap Bio Group and Lonza Collaborate
LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment.